|
|
Volumn 5, Issue 1, 2011, Pages 1-3
|
|
Aspirin, P2Y12 blockers, cilostazol, PAR-1 blockers and emerging antiplatelet therapies: Can biomarkers guide clinical development and practice?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
11 OXOTHROMBOXANE B2;
ACETYLSALICYLIC ACID;
CANGRELOR;
CD40 LIGAND;
CILOSTAZOL;
CLOPIDOGREL;
ELINOGREL;
FIBRINOGEN RECEPTOR ANTAGONIST;
HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;
PADGEM PROTEIN;
PRASUGREL;
PROTEINASE ACTIVATED RECEPTOR 1;
PROTON PUMP INHIBITOR;
PURINERGIC P2Y12 RECEPTOR;
THROMBIN;
THROMBOXANE A2;
THROMBOXANE B2;
TICAGRELOR;
ANTITHROMBOCYTIC AGENT;
BIOLOGICAL MARKER;
PURINERGIC P2Y RECEPTOR ANTAGONIST;
TETRAZOLE DERIVATIVE;
ABCB1 GENE;
ACUTE CORONARY SYNDROME;
COMORBIDITY;
CYTOCHROME P450 2C19 GENE;
CYTOCHROME P450 3A4 GENE;
DRUG DOSE INCREASE;
DRUG RESPONSE;
DRUG SUBSTITUTION;
DRUG WITHDRAWAL;
EDITORIAL;
GENE;
GENETIC POLYMORPHISM;
GENETIC SCREENING;
PERCUTANEOUS CORONARY INTERVENTION;
PERSONALIZED MEDICINE;
THROMBOCYTE ACTIVATION;
THROMBOCYTE AGGREGATION;
DRUG ANTAGONISM;
DRUG DEVELOPMENT;
HUMAN;
METABOLISM;
METHODOLOGY;
ASPIRIN;
BIOLOGICAL MARKERS;
DRUG DISCOVERY;
GENETIC TESTING;
HUMANS;
INDIVIDUALIZED MEDICINE;
PLATELET AGGREGATION INHIBITORS;
PURINERGIC P2Y RECEPTOR ANTAGONISTS;
RECEPTOR, PAR-1;
RECEPTORS, PURINERGIC P2Y12;
TETRAZOLES;
|
|
EID: 79951799280
PISSN: 17520363
EISSN: None
Source Type: Journal
DOI: 10.2217/bmm.11.6 Document Type: Editorial |
|
Times cited : (3)
|
|
References (10)
|
